Voloridge Investment Management LLC Acquires 22,291 Shares of Ascendis Pharma A/S (NASDAQ:ASND)

Voloridge Investment Management LLC raised its holdings in shares of Ascendis Pharma A/S (NASDAQ:ASND) by 1,076.9% in the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 24,361 shares of the biotechnology company’s stock after buying an additional 22,291 shares during the period. Voloridge Investment Management LLC owned about 0.06% of Ascendis Pharma A/S worth $2,346,000 at the end of the most recent quarter.

A number of other hedge funds have also made changes to their positions in ASND. Lindbrook Capital LLC boosted its stake in shares of Ascendis Pharma A/S by 83.2% during the 3rd quarter. Lindbrook Capital LLC now owns 852 shares of the biotechnology company’s stock worth $82,000 after acquiring an additional 387 shares during the last quarter. Tobam purchased a new position in Ascendis Pharma A/S during the second quarter valued at $157,000. First Trust Advisors LP bought a new stake in Ascendis Pharma A/S during the second quarter valued at about $215,000. LPL Financial LLC grew its holdings in Ascendis Pharma A/S by 6.2% during the second quarter. LPL Financial LLC now owns 2,233 shares of the biotechnology company’s stock valued at $257,000 after purchasing an additional 131 shares during the period. Finally, Flinton Capital Management LLC grew its holdings in Ascendis Pharma A/S by 6.7% during the second quarter. Flinton Capital Management LLC now owns 2,304 shares of the biotechnology company’s stock valued at $265,000 after purchasing an additional 144 shares during the period.

Shares of Ascendis Pharma A/S stock opened at $113.75 on Wednesday. Ascendis Pharma A/S has a fifty-two week low of $54.67 and a fifty-two week high of $133.96. The company has a debt-to-equity ratio of 0.05, a quick ratio of 15.75 and a current ratio of 15.74. The company has a market capitalization of $4.85 billion, a P/E ratio of -30.41 and a beta of 0.63. The company has a fifty day moving average of $109.71 and a 200 day moving average of $112.61.

Several research analysts have recently commented on the company. Zacks Investment Research downgraded Ascendis Pharma A/S from a “buy” rating to a “hold” rating in a research note on Friday, November 22nd. ValuEngine downgraded Ascendis Pharma A/S from a “buy” rating to a “hold” rating in a research note on Tuesday. Leerink Swann reissued an “outperform” rating and issued a $152.00 target price (up from $140.00) on shares of Ascendis Pharma A/S in a report on Tuesday. JPMorgan Chase & Co. increased their target price on shares of Ascendis Pharma A/S from $143.00 to $152.00 and gave the stock an “overweight” rating in a report on Thursday, August 29th. Finally, BidaskClub cut shares of Ascendis Pharma A/S from a “sell” rating to a “strong sell” rating in a research note on Thursday, September 12th. One equities research analyst has rated the stock with a sell rating, two have issued a hold rating and eight have given a buy rating to the company. Ascendis Pharma A/S presently has an average rating of “Buy” and an average price target of $150.50.

Ascendis Pharma A/S Profile

Ascendis Pharma A/S, a clinical stage biopharmaceutical company, develops various prodrug therapies for unmet medical needs. The company develops TransCon human growth hormone, which is in Phase III clinical study in children to treat growth hormone deficiency; TransCon parathyroid hormone that is in Phase I clinical study for treating hypoparathyroidism; and TransCon C-type natriuretic peptide for the treatment of achondroplasia.

Featured Article: What Is An Exchange-Traded Fund (ETF)?

Want to see what other hedge funds are holding ASND? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Ascendis Pharma A/S (NASDAQ:ASND).

Institutional Ownership by Quarter for Ascendis Pharma A/S (NASDAQ:ASND)

Receive News & Ratings for Ascendis Pharma A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ascendis Pharma A/S and related companies with MarketBeat.com's FREE daily email newsletter.



Comments


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit